SG11201810471YA - T cell expansion - Google Patents
T cell expansionInfo
- Publication number
- SG11201810471YA SG11201810471YA SG11201810471YA SG11201810471YA SG11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cells
- virus
- london
- herencia
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 230000010261 cell growth Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 4
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000003636 conditioned culture medium Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1107—B cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340605P | 2016-05-24 | 2016-05-24 | |
| US15/290,230 US10052372B2 (en) | 2016-05-24 | 2016-10-11 | T cell expansion |
| PCT/EP2016/075644 WO2017202478A1 (en) | 2016-05-24 | 2016-10-25 | T cell expansion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810471YA true SG11201810471YA (en) | 2018-12-28 |
Family
ID=57886334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810471YA SG11201810471YA (en) | 2016-05-24 | 2016-10-25 | T cell expansion |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10052372B2 (enExample) |
| EP (1) | EP3265555B1 (enExample) |
| JP (1) | JP2019520061A (enExample) |
| KR (1) | KR20190013831A (enExample) |
| CN (1) | CN109563483A (enExample) |
| DK (1) | DK3265555T3 (enExample) |
| ES (1) | ES2742215T3 (enExample) |
| HK (1) | HK1250378B (enExample) |
| PT (1) | PT3265555T (enExample) |
| SG (1) | SG11201810471YA (enExample) |
| TW (1) | TWI660970B (enExample) |
| WO (1) | WO2017202478A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064884T2 (hu) * | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
| WO2017192717A1 (en) | 2016-05-05 | 2017-11-09 | Southwest Research Institute | Three-dimensional bioreactor for cell expansion and related applications |
| US10052372B2 (en) * | 2016-05-24 | 2018-08-21 | Tessa Therapeutics Pte Ltd | T cell expansion |
| EP3920616B1 (en) * | 2017-05-06 | 2023-03-22 | LG Electronics Inc. | D2d operation method by terminal in wireless communication system and terminal using said method |
| WO2019118902A2 (en) * | 2017-12-15 | 2019-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting t cell exhaustion |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| WO2020068840A1 (en) | 2018-09-24 | 2020-04-02 | Southwest Research Institute | Three-dimensional bioreactors |
| WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
| WO2022197933A1 (en) | 2021-03-18 | 2022-09-22 | The Broad Institute, Inc. | Compositions and methods for characterizing lymphoma and related conditions |
| EP4330379A2 (en) | 2021-04-27 | 2024-03-06 | Baylor College of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
| KR20250024750A (ko) | 2022-04-13 | 2025-02-19 | 티크바 알로셀 피티이. 엘티디. | 치료용 t 세포 산물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| WO1999025812A1 (en) | 1997-11-14 | 1999-05-27 | Hemosol Inc. | Method for the production and use of dendritic cells |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| US7651855B2 (en) * | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| JP2013512694A (ja) * | 2009-12-08 | 2013-04-18 | ウィルソン ウォルフ マニュファクチャリング コーポレイション | 養子細胞療法のための細胞を培養する方法 |
| SG11201404677TA (en) * | 2011-12-12 | 2014-11-27 | Cell Medica Ltd | Process of expanding t cells |
| JP6327734B2 (ja) * | 2012-03-07 | 2018-05-23 | 国立大学法人富山大学 | Ｔ細胞の刺激方法およびその利用 |
| US10052372B2 (en) * | 2016-05-24 | 2018-08-21 | Tessa Therapeutics Pte Ltd | T cell expansion |
-
2016
- 2016-10-11 US US15/290,230 patent/US10052372B2/en not_active Expired - Fee Related
- 2016-10-25 CN CN201680086124.3A patent/CN109563483A/zh active Pending
- 2016-10-25 SG SG11201810471YA patent/SG11201810471YA/en unknown
- 2016-10-25 US US16/304,233 patent/US20190269768A1/en not_active Abandoned
- 2016-10-25 PT PT16785490T patent/PT3265555T/pt unknown
- 2016-10-25 KR KR1020187036135A patent/KR20190013831A/ko not_active Withdrawn
- 2016-10-25 WO PCT/EP2016/075644 patent/WO2017202478A1/en not_active Ceased
- 2016-10-25 EP EP16785490.0A patent/EP3265555B1/en not_active Not-in-force
- 2016-10-25 DK DK16785490.0T patent/DK3265555T3/da active
- 2016-10-25 JP JP2018562017A patent/JP2019520061A/ja active Pending
- 2016-10-25 ES ES16785490T patent/ES2742215T3/es active Active
- 2016-10-25 HK HK18108568.5A patent/HK1250378B/en not_active IP Right Cessation
- 2016-10-28 TW TW105135045A patent/TWI660970B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK3265555T3 (da) | 2019-08-12 |
| US20190269768A1 (en) | 2019-09-05 |
| CN109563483A (zh) | 2019-04-02 |
| HK1250378B (en) | 2020-05-08 |
| JP2019520061A (ja) | 2019-07-18 |
| US20170028042A1 (en) | 2017-02-02 |
| US10052372B2 (en) | 2018-08-21 |
| TWI660970B (zh) | 2019-06-01 |
| TW201741330A (zh) | 2017-12-01 |
| KR20190013831A (ko) | 2019-02-11 |
| PT3265555T (pt) | 2019-09-04 |
| EP3265555A1 (en) | 2018-01-10 |
| WO2017202478A1 (en) | 2017-11-30 |
| ES2742215T3 (es) | 2020-02-13 |
| EP3265555B1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810471YA (en) | T cell expansion | |
| SG11201811048UA (en) | Single-cell transcript sequencing | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201806988UA (en) | Improved differentiation method | |
| SG11201810605UA (en) | Selectively altering microbiota for immune modulation | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201810430WA (en) | Heater assembly for an aerosol-generating system | |
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201910101SA (en) | Alphavirus neoantigen vectors | |
| SG11201807025SA (en) | Crispr/cas systems for c-1 fixing bacteria | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807487WA (en) | Generation of midbrain-specific organoids from human pluripotent stem cells | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201806284TA (en) | Low pressure separator having an internal divider and uses therefor | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201806453TA (en) | Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201900058YA (en) | Method of generating mesenchymal stem cells and uses thereof | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201909419XA (en) | Hydrogel for cell culture and biomedical applications |